Literature DB >> 33350419

Exosome-mediated delivery of gene vectors for gene therapy.

Li Duan1, Limei Xu, Xiao Xu, Zhuan Qin, Xiaoying Zhou, Yin Xiao, Yujie Liang, Jiang Xia.   

Abstract

Gene vectors are nucleic acids that carry genetic materials or gene editing devices into cells to exert the sustained production of therapeutic proteins or to correct erroneous genes of the cells. However, the cell membrane sets a barrier for the entry of nucleic acid molecules, and nucleic acids are easily degraded or neutralized when they are externally administered into the body. Carriers to encapsulate, protect and deliver nucleic acid molecules therefore are essential for clinical applications of gene therapy. The secreted organelles, exosomes, which naturally mediate the communications between cells, have been engineered to encapsulate and deliver nucleic acids to the desired tissues and cells. The fusion of exosomes with liposomes can increase the loading capacity and also retain the targeting capability of exosomes. Altogether, this review summarizes the most recent designs of exosome-based applications for gene delivery and their future perspectives in gene therapy.

Mesh:

Substances:

Year:  2021        PMID: 33350419     DOI: 10.1039/d0nr07622h

Source DB:  PubMed          Journal:  Nanoscale        ISSN: 2040-3364            Impact factor:   7.790


  20 in total

1.  Insertion of the Icelandic Mutation (A673T) by Prime Editing: A Potential Preventive Treatment for Familial and Sporadic Alzheimer's Disease.

Authors:  Guillaume Tremblay; Joël Rousseau; Cedric Happi Mbakam; Jacques P Tremblay
Journal:  CRISPR J       Date:  2022-02-07

2.  The evolving paradigm of extracellular vesicles in intercellular signaling and delivery of therapeutic RNAs.

Authors:  Kevin V Morris; Kenneth W Witwer
Journal:  Mol Ther       Date:  2022-05-28       Impact factor: 12.910

Review 3.  The heterogeneity of microglial activation and its epigenetic and non-coding RNA regulations in the immunopathogenesis of neurodegenerative diseases.

Authors:  Chaoyi Li; Jie Ren; Mengfei Zhang; Huakun Wang; Fang Yi; Junjiao Wu; Yu Tang
Journal:  Cell Mol Life Sci       Date:  2022-09-06       Impact factor: 9.207

Review 4.  Recent Advances on the Function and Purification of Milk Exosomes: A Review.

Authors:  Xiaoping Li; Lan Su; Xinling Zhang; Qi Chen; Ying Wang; Zhenwei Shen; Tian Zhong; Ling Wang; Ying Xiao; Xiao Feng; Xi Yu
Journal:  Front Nutr       Date:  2022-06-09

Review 5.  CRISPR-Cas9-Based Technology and Its Relevance to Gene Editing in Parkinson's Disease.

Authors:  Mujeeb Ur Rahman; Muhammad Bilal; Junaid Ali Shah; Ajeet Kaushik; Pierre-Louis Teissedre; Małgorzata Kujawska
Journal:  Pharmaceutics       Date:  2022-06-13       Impact factor: 6.525

6.  In vitro experimental study on the formation of microRNA-34a loaded exosomes and their inhibitory effect in oral squamous cell carcinoma.

Authors:  Wei Deng; Ying Meng; Bin Wang; Chen-Xing Wang; Chen-Xing Hou; Qing-Hai Zhu; Yu-Ting Tang; Jin-Hai Ye
Journal:  Cell Cycle       Date:  2022-04-29       Impact factor: 5.173

Review 7.  Nanoparticle Delivery of CRISPR/Cas9 for Genome Editing.

Authors:  Li Duan; Kan Ouyang; Xiao Xu; Limei Xu; Caining Wen; Xiaoying Zhou; Zhuan Qin; Zhiyi Xu; Wei Sun; Yujie Liang
Journal:  Front Genet       Date:  2021-05-12       Impact factor: 4.599

Review 8.  Exosomal Non-Coding RNAs: Regulatory and Therapeutic Target of Hepatocellular Carcinoma.

Authors:  Haoming Xia; Ziyue Huang; Shuqiang Liu; Xudong Zhao; Risheng He; Zhongrui Wang; Wenguang Shi; Wangming Chen; Zhizhou Li; Liang Yu; Peng Huang; Pengcheng Kang; Zhilei Su; Yi Xu; Judy Wai Ping Yam; Yunfu Cui
Journal:  Front Oncol       Date:  2021-03-26       Impact factor: 6.244

Review 9.  Targeting Cancer with CRISPR/Cas9-Based Therapy.

Authors:  Katarzyna Balon; Adam Sheriff; Joanna Jacków; Łukasz Łaczmański
Journal:  Int J Mol Sci       Date:  2022-01-05       Impact factor: 5.923

Review 10.  Cancer associated-fibroblast-derived exosomes in cancer progression.

Authors:  Chao Li; Adilson Fonseca Teixeira; Hong-Jian Zhu; Peter Ten Dijke
Journal:  Mol Cancer       Date:  2021-12-01       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.